These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Robinson M, Horn J. Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653 [Abstract] [Full Text] [Related]
6. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Li XQ, Andersson TB, Ahlström M, Weidolf L. Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107 [Abstract] [Full Text] [Related]
9. CYP2C19 genotype and the PPIs--focus on rabeprazole. Lim PW, Goh KL, Wong BC. J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346 [Abstract] [Full Text] [Related]
10. Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Langtry HD, Markham A. Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440 [Abstract] [Full Text] [Related]
11. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Caro JJ, Salas M, Ward A. Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776 [Abstract] [Full Text] [Related]
14. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T. Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474 [Abstract] [Full Text] [Related]
15. [Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice]. Mullner K, Molnar B, Tulassay Z. Orv Hetil; 2007 Mar 25; 148(12):543-51. PubMed ID: 17444020 [Abstract] [Full Text] [Related]
16. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Klotz U. Int J Clin Pharmacol Ther; 2006 Jul 25; 44(7):297-302. PubMed ID: 16961157 [Abstract] [Full Text] [Related]
17. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Miner P, Katz PO, Chen Y, Sostek M. Am J Gastroenterol; 2003 Dec 25; 98(12):2616-20. PubMed ID: 14687806 [Abstract] [Full Text] [Related]
18. Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment. Miner P. Aliment Pharmacol Ther; 2004 Nov 25; 20 Suppl 6():20-9. PubMed ID: 15496215 [Abstract] [Full Text] [Related]
19. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Cheer SM, Prakash A, Faulds D, Lamb HM. Drugs; 2003 Nov 25; 63(1):101-33. PubMed ID: 12487624 [Abstract] [Full Text] [Related]
20. An overview of proton pump inhibitors. Der G. Gastroenterol Nurs; 2003 Nov 25; 26(5):182-90. PubMed ID: 14603076 [Abstract] [Full Text] [Related] Page: [Next] [New Search]